Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

Annals of Hematology

Volumn 93, Issue 3, 2014, Pages 403-409

  Vacirca, Jeffrey L ^a   Acs, Peter I ^b   Tabbara, Imad A ^c   Rosen, Peter J ^d   Lee, Peter ^e   Lynam, Eric ^f  

^a N Shore Hematol/Oncol Associates   (United States)

^b Florida Cancer Specialists   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d Providence Saint Joseph Medical Center   (United States)

^e Tower Cancer Research Foundation ^*  (United States)

^f Pharmatech Inc   (United States)

Author keywords

Aggressive lymphoma; Alkylating agents; Bendamustine; CD20; Chemotherapy; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PATIENT DROPOUTS; RECURRENCE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84894303742     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1879-x     Document Type: Article

References (33)

1. Jaffe ES, Harris NL, Stein H et al (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112:4384-4399
2. Jones SE, Grozea PN, Miller TP et al (1985) Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol 3:1318-1324
3. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
4. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
5. Mey UJ, Orlopp KS, Flieger D et al (2006) Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 24:593-600
6. Harting R, Venugopal P, Gregory SA et al (2007) Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma 7:406-412
7. López A, Gutierrez A, Palacios A et al (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80:127-132
8. Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190
9. Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492-1501
10. Ujjani C, Cheson B (2011) Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Future Oncol 1:9-14
11. Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114, Abstract 405
12. Rummel MJ, Niederle N, Maschmeyer G et al (2012) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 30, Abstract 3
13. Moskowitz AJ, Hamlin PA, Gerecitano J et al (2009) Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 114, Abstract 720
14. D'Elia GM, De Angelis F, Breccia M et al (2010) Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. Leuk Res 34(11):300-301
15. DCTD, NCI, NIH, DHHS (2006) Cancer Therapy Evaluation Program: common terminology criteria for adverse events, version 3.0. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed 6 June 2012
16. MedDRA (2008) Medical dictionary for regulatory activities. Version 10.0. Northrop Grumman Corporation, Los Angeles. www.meddramsso.com. Accessed 6 June 2012. Available by subscription
17. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 26:579-86
18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
19. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Aukema SM, Siebert R, Schuuring E et al (2011) Double-hit B-cell lymphomas. Blood 117:2319-2331
21. Friedberg JW (2008) Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22(5):941-952
22. Lee PP, Rosen PJ (2011) Radioimmunotherapy for CD20-positive B-cell non-Hodgkin's lymphoma. Commun Oncol 8:24-31
23. Cheng S, Coffey G, Zhang XH et al (2011) SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 118:6342-6352
24. Lannutti BJ, Meadows SA, Herman SE et al (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling ad cellular viability. Blood 117:591-594
25. Habermann TM (2012) New developments in the management of diffuse large B-cell lymphoma. Hematol Suppl 1:S93-7
26. Choi MY, Kipps TJ (2012) Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 18(5):404-410
27. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al (2011) Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117:5058-5066
28. Weidmann E, Kim SZ, Rost A et al (2002) Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 13(8):1285-1289
29. Rigacci L, Puccini B, Cortelazzo S et al (2012) Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. Ann Hematol 91:1013-1022
30. + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapy. Leuk Lymphoma 53(11):2290-2292
31. Horn J, Kleber M, Hieke S et al (2012) Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 91(10):1579-1586
32. Ohmachi K, Niitsu N, Uchida T et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31(17):2103-2109
33. Corazzeli G, Capobianco G, Arcamone M et al (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 64(5):907-916